In patients undergoing MitraClip implantation, severe systolic heart failure (LVEF ≤30%) was associated with a trend toward higher 12-month mortality compared to LVEF >30% (34% vs 18%, P=0.05).
Cohort (n=121)
No
Does percutaneous mitral valve repair yield comparable clinical and symptomatic outcomes in patients with severe versus mild-to-moderate systolic heart failure?
Percutaneous mitral valve repair provides comparable symptomatic improvement regardless of baseline LVEF, with residual mitral regurgitation rather than baseline systolic impairment driving short-term mortality.
Absolute Event Rate: 34% vs 18%
p-value: p=0.05
AIMS: Edge-to-edge repair of mitral regurgitation (MR) with the MitraClip(®) (MC) system is increasingly applied in advanced heart failure. Our objective was to compare outcomes in patients with mild-to-moderate and severe systolic heart failure. METHODS AND RESULTS: Between February 2010 and July 2012, 121 patients with MR of at least grade 3+ and a mean EuroSCORE II of 10.6% underwent MC implantation. Thirty-nine had a left ventricular ejection fraction (LVEF) of ≤30% (group A) and 82 of >30% (group B). Procedural success was comparable in both groups (100% vs. 95.2%) with multiple (>2) clip implantation in 34% and 25% of patients, respectively. At 12 months, absolute reduction in MR grade (2.3 vs. 2.2) and relative reduction in mitral valve orifice area (48% vs. 42%) were also comparable. New York Heart Association class had improved independent from baseline LVEF (P < 0.001). In-hospital mortality was low in both groups (2.6% vs. 2.4%), but there was a strong trend for higher 12-month mortality in group A (34% vs. 18%, P = 0.05) with no significant difference in the overall rate of major adverse cerebrovascular and cardiac events (36.8% vs. 28.9%, P = 0.38). On multivariate analysis, MR grade after repair was the strongest predictor of mortality (OR 2.121, 95% CI 1.095-4.109), whereas systolic impairment was no independent predictor. CONCLUSIONS: Percutaneous mitral valve repair led to comparable symptomatic improvement in patients with mild-to-moderately or severely reduced LV function. LV-EF < 30% was not an independent predictor of short-term mortality, which was mainly governed by residual MR after repair.
Bozdağ-Turan et al. (Thu,) conducted a cohort in Mitral regurgitation and systolic heart failure (n=121). Severe systolic heart failure (LVEF ≤30%) vs. Mild-to-moderate systolic heart failure (LVEF >30%) was evaluated on 12-month mortality (p=0.05). In patients undergoing MitraClip implantation, severe systolic heart failure (LVEF ≤30%) was associated with a trend toward higher 12-month mortality compared to LVEF >30% (34% vs 18%, P=0.05).